Erudio Healtherudio.com
Sponsor
NRG Oncology trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by NRG Oncology: NRG-GU008. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 18 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (NRG Oncology). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| NRG-GU008 NCT04134260 · NRG Oncology | node-positive prostate cancer after radical prostatectomy | Phase 3 | 304 | 29 | Deep | Nov 15, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NRG-LU002 NCT03137771 · NRG Oncology DeepView → | limited metastatic non-small cell lung cancer | Phase 2 | Deep | View | |||
| NRG-BR002 NCT02364557 · NRG Oncology DeepView → | newly oligometastatic breast cancer | Phase 2/Phase 3 | Deep | View | |||
| CIRCULATE-US NCT05174169 · NRG Oncology DeepView → | stage III colon cancer | Phase 2/Phase 3 | Deep | View | |||
| LAP100 NCT06958328 · NRG Oncology DeepView → | locally advanced unresectable pancreatic ductal adenocarcinoma | Phase 3 | Deep | View | |||
| NRG-GU005 NCT03367702 · NRG Oncology DeepView → | localized intermediate-risk prostate cancer | Phase 3 | Deep | View | |||
| NRG-GU006 NCT03371719 · NRG Oncology DeepView → | recurrent prostate cancer | Phase 2 | Deep | View | |||
| NRG-GI003 NCT03186898 · NRG Oncology DeepView → | unresectable hepatocellular carcinoma | Phase 3 | Deep | View | |||
| OFSET NCT05879926 · NRG Oncology DeepView → | premenopausal ER-positive/HER2-negative breast cancer, Oncotype recurrence score ≤25 | Phase 3 | Deep | View | |||
| PREDICT-RT NCT04513717 · NRG Oncology DeepView → | high risk prostate cancer | Phase 3 | Deep | View | |||
| NRG-GY036 NCT06580314 · NRG Oncology StandardView → | BRCA1/2-mutated or HRD+ ovarian cancer | Phase 3 | Standard | View | |||
| NRG-GY019 NCT04095364 · NRG Oncology StandardView → | stage II-IV low-grade serous ovarian cancer | Phase 3 | Standard | View | |||
| NRG-BN001 NCT02179086 · NRG Oncology StandardView → | newly diagnosed glioblastoma | Phase 2 | Standard | View | |||
| NRG Promethean NCT05053152 · NRG Oncology FocusedView → | oligometastatic prostate cancer | Phase 2 | Focused | View | |||
| SAMURAI NCT05327686 · NRG Oncology FocusedView → | metastatic unresected renal cell carcinoma | Phase 2 | Focused | View | |||
| COBRA NCT04068103 · NRG Oncology FocusedView → | Not given | Phase 2/Phase 3 | Focused | View | |||
| RADIATE-LM NCT06500481 · NRG Oncology FocusedView → | breast or non-small cell lung cancer leptomeningeal metastasis | Phase 3 | Focused | View | |||
| NADIR NCT04037254 · NRG Oncology FocusedView → | high-risk prostate cancer | Phase 1/Phase 2 | Focused | View | |||
| NCT05624996 NCT05624996 · NRG Oncology FocusedView → | Not given | Phase 3 | Focused | View | |||